Navigating Tumor Angiogenesis: Therapeutic Perspectives and Myeloid Cell Regulation Mechanism

Overview

Journal Angiogenesis

Publisher Springer

Specialty Hematology

Date 2024 Apr 5

PMID 38580870

Authors

Fan Yang

Gloria Lee

Yi Fan

Affiliations

Soon will be listed here.

Abstract

Sustained angiogenesis stands as a hallmark of cancer. The intricate vascular tumor microenvironment fuels cancer progression and metastasis, fosters therapy resistance, and facilitates immune evasion. Therapeutic strategies targeting tumor vasculature have emerged as transformative for cancer treatment, encompassing anti-angiogenesis, vessel normalization, and endothelial reprogramming. Growing evidence suggests the dynamic regulation of tumor angiogenesis by infiltrating myeloid cells, such as macrophages, myeloid-derived suppressor cells (MDSCs), and neutrophils. Understanding these regulatory mechanisms is pivotal in paving the way for successful vasculature-targeted cancer treatments. Therapeutic interventions aimed to disrupt myeloid cell-mediated tumor angiogenesis may reshape tumor microenvironment and overcome tumor resistance to radio/chemotherapy and immunotherapy.

Citing Articles

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.

Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.

Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T Biomark Res. 2025; 13(1):38.

PMID: 40045379 PMC: 11884212. DOI: 10.1186/s40364-025-00745-7.

Roles and therapeutic potential of the SLC family in prostate cancer-literature review.

Fu Y, Chen J, Zhu X, Ding M, Wang H, Fu S BMC Urol. 2025; 25(1):32.

PMID: 39966814 PMC: 11837367. DOI: 10.1186/s12894-025-01714-w.

Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?.

Failla C, Carbone M, Ramondino C, Bruni E, Orecchia A Biomedicines. 2025; 13(1).

PMID: 39857591 PMC: 11763294. DOI: 10.3390/biomedicines13010006.

Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.

Biray Avci C, Bagca B, Nikanfar M, Takanlou L, Takanlou M, Nourazarian A Front Pharmacol. 2024; 15:1442888.

PMID: 39600368 PMC: 11588459. DOI: 10.3389/fphar.2024.1442888.

References

Carmeliet P, Jain R . Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307. PMC: 4049445. DOI: 10.1038/nature10144. View

Fridman W, Pages F, Sautes-Fridman C, Galon J . The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12(4):298-306. DOI: 10.1038/nrc3245. View

Tian L, Goldstein A, Wang H, Lo H, Kim I, Welte T . Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017; 544(7649):250-254. PMC: 5788037. DOI: 10.1038/nature21724. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

Weis S, Cheresh D . Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17(11):1359-70. DOI: 10.1038/nm.2537. View

Cao Y, Langer R, Ferrara N . Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023; 22(6):476-495. DOI: 10.1038/s41573-023-00671-z. View

Ebos J, Kerbel R . Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011; 8(4):210-21. PMC: 4540336. DOI: 10.1038/nrclinonc.2011.21. View

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Liu T, Ma W, Xu H, Huang M, Zhang D, He Z . PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat Commun. 2018; 9(1):3439. PMC: 6110798. DOI: 10.1038/s41467-018-05982-z. View

10.

Bergers G, Benjamin L . Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3(6):401-10. DOI: 10.1038/nrc1093. View

11.

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

12.

Carmeliet P, Jain R . Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011; 10(6):417-27. DOI: 10.1038/nrd3455. View

13.

Martin J, Seano G, Jain R . Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. Annu Rev Physiol. 2019; 81:505-534. PMC: 6571025. DOI: 10.1146/annurev-physiol-020518-114700. View

14.

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

15.

Turner N, Grose R . Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10(2):116-29. DOI: 10.1038/nrc2780. View

16.

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

17.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

18.

Lee P, Goishi K, Davidson A, Mannix R, Zon L, Klagsbrun M . Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci U S A. 2002; 99(16):10470-5. PMC: 124944. DOI: 10.1073/pnas.162366299. View

19.

Benedito R, Rocha S, Woeste M, Zamykal M, Radtke F, Casanovas O . Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature. 2012; 484(7392):110-4. DOI: 10.1038/nature10908. View

20.

Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani A . Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2012; 73(1):108-18. DOI: 10.1158/0008-5472.CAN-12-2064. View